GENinCode Plc (AIM:GENI)

Market Cap	8.10M +10.2%
Revenue (ttm)	2.91M +12.1%
Net Income	-4.97M
EPS	-0.02
Shares Out	753.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,415,740
Average Volume	5,466,936
Open	1.075
Previous Close	1.075
Day's Range	1.075 - 1.100
52-Week Range	0.900 - 5.500
Beta	0.64
RSI	28.09
Earnings Date	Jun 4, 2026

About GENinCode

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular pre...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2018
• Employees: 42
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: GENI

Financial Performance

In 2024, GENinCode's revenue was 2.70 million, an increase of 25.05% compared to the previous year's 2.16 million. Losses were -4.43 million, -36.80% less than in 2023.